In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...

Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir. The Indian ...

Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Baylen, Paige Cowett, Rowan Niemisto, Dan Powell, Elisheba Ittoop, Marion Lozano and Alyssa Moxley Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...

Drugmaker Gilead has announced that its new ... The company will next seek approval from the U.S. Food and Drug Administration (FDA) to market lenacapavir as an HIV treatment.